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Woodchuck hepatitis virus (WHV) and hepatitis B virus (HBV) are closely similar with respect to genomic
organization, host antiviral responses, and pathobiology of the infection. T-cell immunity against viral nu-
cleocapsid (HBcAg or WHcAg) has been shown to play a critical role in viral clearance and protection against
infection. Here we show that vaccination of healthy woodchucks by gene gun bombardment with a plasmid coding
for WHcAg (pCw) stimulates proliferation of WHcAg-specific T cells but that these cells do not produce sig-
nificant levels of gamma interferon (IFN-) upon antigen stimulation. In addition, animals vaccinated with pCw
alone were not protected against WHV inoculation. In order to induce a Th1 cytokine response, another group
of woodchucks was immunized with pCw together with another plasmid coding for woodchuck interleukin-12
(IL-12). These animals exhibited WHcAg-specific T-cell proliferation with high IFN- production and were pro-
tected against challenge with WHV, showing no viremia or low-level transient viremia after WHV inoculation.
In conclusion, gene gun immunization with WHV core generates a non-Th1 type of response which does not
protect against experimental infection. However, steering the immune response to a Th1 cytokine profile by IL-
12 coadministration achieves protective immunity. These data demonstrate a crucial role of Th1 responses in the
control of hepadnavirus replication and suggest new approaches to inducing protection against HBV infection.
Hepatitis B virus (HBV) is a partially double-stranded DNA
virus encoding envelope (pre-S1, pre-S2, HBsAg), nucleocap-
sid (HBcAg, HBeAg), trans-activating (X), and polymerase
(Pol) proteins (46). Clinical manifestations of HBV infection
range from acute and chronic hepatitis to cirrhosis and hepa-
tocellular carcinoma in humans (6). There are more than 350
million chronic HBV carriers worldwide (54), and HBV is an
important cause of morbidity and mortality in the Third World.
Several reports have shown that the immune response plays
a significant role in both HBV clearance and pathogenesis of
hepatitis B (13). A vigorous polyclonal and multispecific cel-
lular response to HBV has been associated with recovery from
acute infection. Cytotoxic T lymphocytes (CTLs) and T-helper
(Th) cells with specificity for HBcAg and most HBV proteins
can be detected in the circulation during acute infection (22,
34, 37). In contrast, defective CTL and Th cell responses are
observed in chronic HBV carriers, except during exacerbation
(48). As has been reported for several viral infections, a pref-
erential induction of a Th1 type T-helper response with pro-
duction of gamma interferon (IFN-) may be crucial in the
control of HBV infection (2). Interleukin 12 (IL-12) is a het-
erodimeric molecule, produced by activated antigen-present-
ing cells (APCs), which plays a key role in the activation of Th1
responses. IL-12 promotes the maturation of Th1 cells from an
uncommitted T-cell pool and stimulates the production of
IFN- by Th1 cells, CTLs, and NK cells (47).
The woodchuck (Marmota monax) is readily infected with
woodchuck hepatitis virus (WHV), providing a valuable animal
model in which to study the pathogenesis, prevention, and
treatment of HBV infection (7, 38, 45). The genomic organi-
zation and replicative cycle of WHV and the proteins encoded
by WHV DNA are very similar to those of HBV (12, 14). Like
HBV, WHV induces acute self-limited hepatitis in adult ani-
mals in most cases, while perinatal infection may cause chronic
hepatitis which may evolve to hepatocellular carcinoma (35).
Because of similarities between HBV and WHV infections
(49), the woodchuck model is a useful system for the study of
prophylactic and therapeutic vaccines (19, 28, 39, 40).
The current HBV vaccine contains HBs protein and confers
protection via anti-HBs antibodies (18, 23). However, approx-
imately 5 to 10% of vaccinees do not develop humoral immu-
nity (5, 24), and, on the other hand, HBsAg escape viral mu-
tants may occur in infected patients (4, 5). Moreover, the HBs
vaccine is of little efficacy in controlling established chronic
HBV infection (10; Y. M. Wen, X. H. Wu, D. C. Hu, Q. P.
Zhang, and S. Q. Guo, Letter, Lancet 345:1575–1576, 1995).
Immunization with HBcAg or WHV core antigen (WHcAg)
can efficiently induce CTL responses and prevent infection in
the chimpanzee and in woodchucks (21, 25, 28, 32, 39, 40).
These viral protein antigens, although unable to induce neu-
tralizing antibodies, may stimulate protective immunity by
priming Th cells that support a specific CTL response, leading
to early clearance of virus (29, 42).
Lu et al. (28) demonstrated that intramuscular injection
of plasmids coding for WHV surface antigen (WHsAg) or
WHcAg elicited immune responses which protected wood-
chucks against challenge with WHV. However, protective im-
munity was obtained after three immunizations with 1 mg of
plasmid DNA (28). Gene gun technology has gained accep-
tance as a method for genetic vaccination using very low doses
of immunogen. This method consists of a biolistic device that
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propels gold particles coated with plasmid DNA into the skin
by means of pressurized helium. It allows efficient delivery
of DNA to APCs of the skin, which after synthesis and pro-
cessing present the antigen to major histocompatibility com-
plex (MHC) class I and class II molecules (36, 43). This im-
munization system can elicit cellular and humoral immune
responses which mimic those to live attenuated virus vaccines
while avoiding some of the possible problems associated with
live vaccines. Gene gun vaccination is a safe and inexpensive
procedure which has been shown to be effective against various
pathogens including HBV (11, 30, 50–53). In the present work,
we have investigated the effects of gene gun immunization with
WHcAg to elicit T-cell immunity. We found that although this
vaccination induced proliferation of WHcAg-specific T cells,
these T cells were unable to produce IFN- and animals did
not show protection against WHV inoculation. However, gene
gun immunization with WHcAg plus woodchuck IL-12 gener-
ated a Th1 immune response and efficient protective immunity.
MATERIALS AND METHODS
Animals. Twelve uninfected woodchucks (purchased from Northeastern Wild-
life, Ithaca, N.Y.), handled according to the guidelines of our institution (Centro
de Investigacio´n en Farmacobiologı´a Aplicada [CIFA], Pamplona, Spain), were
used. All animals were negative for WHsAg, WHV DNA, anti-WHV surface
antibodies (anti-WHs) and anti-WHV core antibodies (anti-WHc). Blood was
collected from the saphena vein of the hind legs under anesthesia.
Female BALB/c mice (10 to 20 weeks old) were purchased from Charles River
(Barcelona, Spain) and housed according to our institution’s guidelines.
Construction and characterization of expression vectors pCw and pIL12w. A
DNA fragment (nucleotides 2022 to 2586) coding for WHcAg was amplified by
PCR from plasmid pBR325-WHV (16) using specific primers (Table 1). PCR
was performed by following standard protocols. PCR products were purified by
the Concert Rapid Gel Extraction System (Life Technologies, Gibco BRL, Eg-
gestein-Leopoldshafen, Germany), cloned into the pcDNA3-T vector (Invitro-
gen, San Diego, Calif.), and sequenced with an ABI Prism Cycle Sequencing kit
(Applied Biosystems, Foster City, Calif.), followed by automated capillary elec-
trophoresis in an ABI Prism 310 Genetic Analyzer. The resulting plasmid was
named pCw.
Expression of WHcAg was confirmed by a coupled transcription-translation
reaction using the TNT T7 Quick Transcription/Translation System (Promega,
Madison, Wis.) according to the manufacturer’s instructions. Proteins were an-
alyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and autoradiography, following standard protocols (1). A band corre-
sponding to the putative molecular weight of WHcAg was obtained (data not
shown).
Plasmid coding for woodchuck interleukin 12 (pIL12w) was prepared by
reverse transcription (RT)-PCR amplification from 3  106 peripheral blood
mononuclear cells (PBMC), which were stimulated with lipopolysaccharide
(LPS) (20 ng/ml) at 37°C and 5% CO2 for 5 h. Primers for p35 and p40 cloning
(Table 1) were designed according to previously reported sequences (GenBank
accession number X97018 for p35 and X97019 for p40). RTs (1 h at 37°C and 5
min at 95°C) for p35 and p40 were performed in a final volume of 20 l
containing 1 g of RNA and 500 nM reverse primer, 1  RT buffer, 5.5 mM
MgCl2, 2 mM deoxynucleoside triphosphates (dNTPs), 0.4 U of RNAse inhibi-
tor/l, and 1.25 U of murine leukemia virus (MuLV) reverse transcriptase
(Applied Biosystems)/l. The resulting cDNA was then amplified by following
standard protocols (annealing temperatures, 48.7°C for p35 amplification and
58°C for p40). PCR-derived products, 691-bp (p35) and 1,026-bp (p40) frag-
ments, were cloned into pCR2.1 TOPO vectors (Invitrogen) according to the
manufacturer’s guidelines. p40 was then removed by NcoI and XbaI digestion,
and the fragment was cloned into a similarly digested pCITE-1 vector (Novagen,
Madison, Wis.), a plasmid containing an internal ribosome entry site (IRES). An
EcoRI fragment containing an IRES followed by p40 was then excised, blunt
ended, and subcloned into pcDNA3 opened with EcoRV. The final plasmid,
named pIL12w, was constructed by inserting (by blunt-end ligation) a HindIII
fragment containing p35 into pcDNA3 IRESp40 linearized with BamHI.
pIL12w was characterized by sequencing and by a coupled transcription-
translation reaction, using the TNT T7 Quick Transcription/Translation System
(Promega) according to the manufacturer’s instructions.
To determine the biological activity of pIL12w, we transfected 293 cells with
pIL12w or pEGFP-N1 (Clontech, Palo Alto, Calif.), a plasmid coding for en-
hanced green fluorescent protein, using polyethylenimine (PEI; generously pro-
vided by J. P. Behr) as described elsewhere (3). Supernatants (500 l/well) from
the transfected cells were added to woodchuck PBMC (3  106 cells/well)
extracted as previously described (19). After 24 h of culture, induction of IFN-
mRNA was determined by quantitative PCR as described below.
Immunization protocol. Plasmids pIL12w and pCw were used to prepare
complexes of DNA with gold beads (diameter, 1.6 m) as described elsewhere
(20). Gene gun immunizations were delivered to shaved abdominal skin of mice
or woodchucks using the Helios Gene Gun (Bio-Rad, Hercules, Calif.) at a
helium discharge pressure of 400 to 450 lb/in2.
Female BALB/c mice were immunized with different doses of pCw. Each
TABLE 1. Primers used for construction of pCw and pIL12w, and primers and probes used for real-time quantitative PCR
of cytokines and WHV-DNA
Template
DNA Oligonucleotide sequences Probe
Genome localiza-
tion or GenBank
accession no.
p35a Forward, AAGCTT GCCACC ATG TGTCCATCAGC AF288520
Reverse, AAGCTT CTA AGAAGAATTCAGATAGCTCATCACC
p40a Forward, TTCATA CCATGG CCATGTGTCTTCAGCAGTTG AF288519
Reverse, ACGCGT TCTAGA GAATTC CTAAGGGCAGGAC
WHcAgb Forward, TTTTCAAGAAGCCTCCAAGCTGT 1956–1976d
Reverse, GTTTTATGTACCCATTGAAG 2585–2605d
WHcAgc Forward, AGAAGACGCACTCCCTCTCCT AGAAGATCTCAATCACCGCGTCGCAG 2501–2580d
Reverse, TGGCAGATGGAGATTGAGAGC
IFN-c Forward, CAGATGGCGGGTCTCTCCTTC TGGATATTTTGGATAAATGGAAAGAGGA 137–244e
Reverse, GACAACTTGGCTCTGGATTACTTTT
-Actinc Forward, TCACCCACACTGTGCCCATCTACGA ATGCCCTCCCCCATGCCATCCTGCGT 2141–2381e
Reverse, CAGCGGAACCGCTCATTGCCAATGG
a Primers used to construct pIL12w, for amplification of p35 and p40 woodchuck IL-12 subunits.
b Primers used for construction of the pCw vector
c Primers and probes for quantitative PCR.
d Source: Kodama et al. (24a).
e Source: Nakamura et al. (33).
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animal received two nonoverlapping shots with bullets containing 0.5 mg of gold
particles at a concentration of 2 g of DNA/mg of Au (group 1) or 4 g of
DNA/mg of Au (group 2) in the abdominal skin. Mice were immunized three
times at 2-week intervals for a total dose of 6 g (group 1) or 12 g (group 2) of
pCw.
Three groups of woodchucks were immunized using the Gene Gun with bullets
containing 0.5 mg of gold particles at a concentration of 4 g of DNA/mg of Au.
The protocol consisted of three immunization sessions, separated by 2-week
intervals, with four shots per session, on different areas of the abdominal skin.
Group 1 woodchucks (WC1, WC2, WC3, and WC4) were immunized with pCw
(8 g per session). Group 2 woodchucks (WILC1, WILC2, WILC3, WILC4, and
WILC5) were immunized sequentially with pCw and pIL12w (8 g of each
plasmid per session). To ensure colocalized expression of WHcAg and IL12w,
every shot of pCw was followed by a shot of pIL12w delivered into exactly the
same area of the skin. Group 3 was used as a control and consisted of two
nonimmunized woodchucks (WN1 and WN2) and a woodchuck (WN3) that was
subjected to the group 1 immunization protocol but received 8 g of empty
plasmid pcDNA3 in each immunization session.
Challenge with WHV. Four weeks after completion of the vaccination proto-
col, immunized and non-immunized animals were challenged by subcutaneous
injection of an inoculum containing 1010 WHV genomic particles. The inoculum
was a serum sample obtained from a chronically infected woodchuck. The titer
was calculated by dot blot hybridization (19), using a digoxigenin-labeled
WHsAg probe obtained by PCR amplification using a commercially available
labeling mix (Boehringer Mannheim, GmbH, Mannheim, Germany).
Immunological studies, determations of levels of viral DNA in serum, and
identification of serological markers were carried out using blood samples ob-
tained weekly during a 10-week follow-up period and also at week 24 postinfec-
tion.
Serology. Enzyme-linked immunosorbent assay (ELISA) techniques were used
to determine levels of anti-WHc, anti-WHs, and WHsAg in serum as previously
reported (19, 39). WHsAg was isolated from a serum pool of a chronically
infected woodchuck as previously reported (15, 19). Recombinant WHcAg was
produced by expression of a plasmid containing the WHc gene kindly provided
by M. Roggendorf (40). Antibody titers are given as the serum dilutions at which
the absorbance value was twice the value of a negative control (a 1/10 dilution of
a serum sample from an uninfected woodchuck).
Determination of WHV DNA levels. Serum WHV DNA was quantified by
real-time quantitative PCR. WHV DNA was isolated from 100 l of serum using
the High Pure Viral Nucleic Acid Kit (Boehringer Mannheim) according to the
following manufacturer’s instructions. Primers and a TaqMan probe (Applied
Biosystems) for WHV core were designed using Primer-express software (Ap-
plied Biosystems) (Table 1). The reaction was performed in a 25-l volume with
2 l of sample, 1 Taqman buffer, 0.4 mM dNTPs, 0.01 U of Amperase/l, 0.05
U of BioTaq DNA polymerase (Bioline, London, United Kingdom)/l, MgCl2 at
5.5 mM, 300 nM each primer, and 100 nM probe. After PCR using the Light-
Cycler system (Roche Diagnostics), the copy number of WHV DNA in each
sample was determined by interpolation, using an external standard consisting of
serial dilutions (108 to 103) of pCw.
IL-2 production bioassay. PBMC from each woodchuck were isolated at dif-
ferent time points as previously described (19). Cells were added in triplicate to
a 96-well flat-bottom plate (4  105 cells/well) and cultured at 37°C and 5% CO2
in complete culture medium (RPMI 1640, 10% fetal bovine serum, 100 U of
penicillin/ml, 100 g of streptomycin/ml, and 2  105 M -mercaptoethanol) in
the presence or absence of 10 g of WHcAg/ml (recombinant WHcAg was
obtained as mentioned above). Fifty microliters of culture supernatant was col-
lected after 24 h of culture and tested for IL-2 content using the CTL-L bioassay
as previously described (26). Results are expressed in terms of the stimulation
index (SI), which is the ratio of the mean counts  min1 incorporated in the
presence of antigen to the mean counts  min1 obtained in the absence of
antigen.
Quantitation of IFN- mRNA in PBMC. PBMC were cultured at 37°C and 5%
CO2 in flat-bottom 24-well plates (3  106 cells/well) in complete medium
containing 10 g of WHcAg/ml. After 24 h of culture, total RNA was extracted
using the Ultraspec-II system (Biotecx Laboratories. Houston, Tex.) following
the manufacturer’s instructions and finally diluted in 40 l of RNase-free water.
An RT reaction was performed in a final volume of 105 l containing 840 ng of
RNA and 1 RT buffer, 5.5 mM MgCl2, 2 mM dNTPs, 2.5 M random hex-
amers, 0.4 U of RNAse inhibitor/l, and 1.25 U of MuLV reverse transcriptase
(Applied Biosystems)/l. Parameters used were 10 min at 25°C, 30 min at 48°C,
and 5 min at 95°C. Primers and Taqman probes (Applied Biosystems) for IFN-
and -actin were designed according to the published cDNA sequences of wood-
chuck genes (33) using Primer-Express software (Table 1). PCR was carried out
in 25 l with 12.5 l of the RT reaction product (containing cDNA correspond-
ing to 100 ng of the original RNA), 1 Taqman buffer, 0.4 mM dNTPs, 0.01 U
of Amperase/l, 0.05 U of BioTaq DNA polymerase (Bioline)/l, 300 nM each
primer, and 200 nM probe. PCR was performed according to the following
parameters: 2 min at 50°C for Amperase digestion, initial denaturation for 15 at
94°C, and 45 cycles of 0.1 s at 95°C and hybridization/elongation for 20 s at 60°C.
Fluorescent signals generated during PCR amplification were monitored using
the LightCycler System (Roche Diagnostics). Numbers of copies of IFN- and
-actin cDNAs were determined by interpolation, using external RNA standards.
The threshold for IFN- and -actin detection was 100 copies. For preparation
of the standard curves, IFN- and -actin fragments were cloned into pCR2.1.
TOPO (Invitrogen), containing a T7 promoter and in vitro transcribed with T7
RNA polymerase. The RNA concentration was estimated by optical density, and
the copy number was calculated from the concentration, mean molecular weight
of nucleotides (330 g/mol), and RNA length.
Statistical analysis. Statistical analysis for anti-WHc, anti-WHs, and viremia
was performed using the Kruskal-Wallis test and the Mann-Whitney U test.
Differences were considered significant at a P value of 0.05. Pearson’s 2 was
used in the analysis of IL-2 and IFN- production and was considered significant
at a P value of 0.05.
RESULTS
Cloning and characterization of pIL12w. RNA extracted
from LPS-stimulated woodchuck PBMC was used to amplify
the p35 and p40 subunits of the IL-12 gene. PCR primers
derived from a previously reported sequence for the p35 and
p40 subunits of woodchuck IL-12 (GenBank accession number
X97018 for p35 and X97019 for p40) were used to obtain the
corresponding PCR products. Alignment of the previously
reported sequences with those obtained from our group
(AF288520 for p35 and AF288519 for p40) revealed two amino
acid changes for the p35 subunit and three for the p40 subunit.
Plasmid pIL12w was constructed based on the sequences that
we obtained with an IRES between p35 and p40 (see Materials
and Methods). The protein encoded by pIL12w was character-
ized by in vitro transcription and translation, which revealed
two fragments with sizes consistent with p40 and p35 subunits
without glycosylation (data not shown).
The biological activity of the resulting protein was tested by
the ability of supernatants from 293 cells, transfected with
pIL12w or a control plasmid (pEGFP-N1), to induce the pro-
duction of IFN- by woodchuck PBMC. The number of copies
of IFN- mRNA per copy of -actin mRNA in PBMC stimu-
lated with supernatants from pIL12w-transfected cells was
46.36, while IFN-mRNA remained undetectable in PBMC in-
cubated with supernatants from pEGFP-N1-transfected cells.
These results indicate that pIL12w encodes biologically active
woodchuck IL-12; to our knowledge, this is the first study in
which functional woodchuck IL-12 gene has been used.
Induction of a specific immune response against WHV core
by gene gun immunization. In order to see whether gene gun
bombardment with pCw was able to elicit an immune response
against WHcAg, we vaccinated two groups of mice (n	 3) with
three doses of pCw at 2-week intervals: the first group received
2 g of pCw per immunization session, and the second re-
ceived 4 g per session. We found that both immunization
protocols were effective at inducing anti-WHc antibodies; the
titers in the two groups of animals were similar (data not
shown).
After the ability of pCw to act as an immunogen was con-
firmed, woodchucks were vaccinated by gene gun bombard-
ment of the skin with pCw alone or together with pIL12w.
Animals WC1 to WC4 (group 1) received three vaccination
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sessions at 2-week intervals with pCw alone, and woodchucks
WILC1 to WILC5 (group 2) were immunized in a similar way
with pCw and pIL12w, the two plasmids being delivered at
exactly the same points of the skin. A control group (group 3)
of three woodchucks (WN1, WN2, and WN3) was also includ-
ed. WN1 and WN2 were not immunized, and WN3 received
empty plasmid pcDNA3 by the same protocol as group 1.
Two weeks after completion of the vaccination protocol,
anti-WHc was undetectable in control animals as well as in
three (WC2, WC3, and WC4) of the four woodchucks immu-
nized with pCw alone. Only WC1 developed a high titer of
anti-WHc antibodies, with values of 711 after the third dose of
the immunogen. By contrast, all animals immunized with pCw
plus pIL12w produced anti-WHc antibodies 2 weeks after com-
pletion of the immunization protocol (Fig. 1A).
Production of IL-2 (Fig. 1B) and IFN- (Fig. 1C) by PBMC
in response to WHcAg was measured in some animals from
each group. While no IL-2 synthesis was found in control
animals, specific IL-2 production against WHcAg was observed
in three (WC1, WC2, and WC3) of four animals immunized
with pCw and in four of four tested animals immunized with
pCw plus pIL12w. SI values ranged between 10 and 30 in the
two immunized groups. WC4 developed a proliferative re-
sponse (SI 	 21) and low levels of anti-WHc antibodies after
a second round of three immunizations with pCw.
At the end of the immunization protocol, IFN- mRNA
production was low in the two nonimmunized animals tested
(0.02 and 0.3 copies of IFN- mRNA per copy of -actin
mRNA) and also in the two tested animals which had been
immunized with pCw alone (0.017 copy in one and undetect-
able levels in the other) (Fig. 1C). In contrast, substantial
amounts of IFN- were found in animals immunized with the
combination of pCw plus pIL12w, ranging from 3 to 4 copies in
WILC1, WILC3, and WILC5 to as many as 200 copies in
WILC2 (Fig. 1C).
Influence of vaccination on the evolution of WHV infection.
To test the protective effect of gene gun vaccination against
WHV infection, woodchucks from the three experimental
groups were challenged subcutaneously with an inoculum con-
taining 1010 genomic copies of WHV. Viral serology was in-
vestigated weekly during a follow-up period of 10 to 12 weeks
and at week 24.
As shown in Fig. 2A, all nonvaccinated animals developed
acute infections, with viremia lasting for 4 to 6 weeks starting
at week 2 or 3 after infection. WHV DNA levels were about
105 genomic copies/l, with peaks of 106 or 107 copies/l in
woodchucks WN2 and WN1, respectively. WHsAg was de-
tected in serum for 7, 1, and 4 weeks in woodchucks WN1,
WN2, and WN3 respectively (Table 2).
No protection against infection was observed in animals
immunized with pCw (Fig. 2B) except for animal WC1, which
showed short-lived viremia of low intensity (a sporadic value of
3  104 copies/l) and remained WHsAg negative (Table 2).
Two woodchucks from this group showed higher levels of
WHV DNA and viremia of longer duration than those ob-
served in nonimmunized animals (Fig. 2A and B). Serum sam-
ples were positive for WHsAg for 2, 9, and 24 weeks for WC2,
WC4, and WC3, respectively. Woodchuck WC3 developed
chronic infection, an event which is exceptional when WHV
infection occurs after the perinatal period.
In contrast with animals immunized with pCw alone, all
woodchucks vaccinated with a combination of pCw and
pIL12w showed protection against WHV infection (Fig. 2C).
Three of these animals (WILC3, WILC4, and WILC5) exhib-
ited undetectable levels of WHV-DNA in serum after infec-
FIG. 1. Immune response against WHcAg following gene gun im-
munization with pCw (stippled bars) or pCw plus pIL12w (hatched
bars). Nonimmunized woodchucks (shaded bars) served as controls.
(A) Humoral immune response. (B) Production of IL-2 by woodchuck
PBMC incubated in the presence of WHcAg. (C) IFN- mRNA levels
(as determined by real-time quantitative RT-PCR) in woodchuck
PBMC incubated in the presence of WHcAg. , animal in which a
second round of immunizations with pCw induced anti-WHcAg anti-
bodies (titer 	 90) and IL-2 production (SI 	 21). , healthy control
animal that was not further infected or followed up.
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tion, whereas the other two (WILC1 and WILC2) presented
low-level viremia (below 105 copies/l) at only one or two time
points during follow-up. While no significant differences in
postinfection WHV DNA levels were found between controls
and pCw-vaccinated woodchucks, the levels of viremia at
weeks 4, 5, and 6 in animals immunized with pCw plus pIL12w
were significantly lower (p0.05) than those in the other two
groups. Only one of the five woodchucks (WILC3) immunized
with pCw plus pIL12w showed a single positive WHsAg value
at week 1 (Table 2), which might result from the inoculum used
for challenge. The other four animals remained WHsAg neg-
ative during follow-up.
Antiviral immunity after WHV infection. Figure 3A shows
the mean levels of anti-WHc antibodies in the three experi-
mental groups. It is noteworthy that while anti-WHc titers were
high in pCw-vaccinated woodchucks, they were low in animals
immunized with pCw in combination with pIL12w. In the last
group the levels of anti-WHc antibodies at weeks 8, 9, and 10
were significantly lower than those in controls (P  0.05) and
in pCw-vaccinated animals (P  0.02).
Similarly to what occurs in HBV infection (23), the devel-
opment of anti-WHs antibodies provides immunity to WHV
(9). As represented in Fig. 3B, animals from the control group
developed high levels of anti-WHs antibodies after infection,
coinciding with the decline of viremia. Anti-WHs levels tended
to be lower in the two groups of vaccinated animals, especially
in the group receiving the combined immunization with pCw
and pIL12w (in this group anti-WHs levels at week 6 were
significantly lower than those in the other two experimental
groups taken together; P  0.05). These data indicate that
animals vaccinated with pCw plus pIL12w were able to clear
WHV with little contribution of humoral immunity.
T-cell responses against WHcAg were analyzed for the three
groups of animals at different time points after infection by
determining the production of IL-2 and IFN- (a Th1 cyto-
kine) by PBMC incubated in the presence of recombinant
WHcAg. As shown in Fig. 4A, after WHV challenge the two
control woodchucks tested (WN1 and WN2) showed low levels
of IL-2 production in response to WHcAg (SI values between
2 and 8) and only a modest elevation in the production of
IFN- (maximal values, 4.5 copies of IFN- mRNA/copy of
-actin mRNA at week 10 in WN3 and 0.24 at week 6 in WN1)
(Fig. 4D).
Figure 4B shows the production of IL-2 in response to
FIG. 2. Evolution of viremia after challenge with WHV. (A) Con-
trol nonimmunized animals; (B) animals immunized with pCw, (C)
woodchucks immunized with pCw plus pIL12w. Inoculation of WHV
was performed at week 0. WHV DNA was quantified by real-time
quantitative PCR. WHV DNA is expressed as genomic particles per
microliter of serum.
TABLE 2. Influence of different immunization protocols on
serum WHsAg after WHV challenge
Treatment Woodchuck Period of WHsAg positivityin serum (wks)
Immunization with
pCw (group 1)
WC1 0
WC2 2 (wk 2 and 3 postinfection)
WC3 24 (wk 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
and 24 postinfection)
WC4 9 (wk 4, 5, 6, 7, 8, 9, 10, and 12
postinfection)
Immunization with
pCw plus pIL12w
(group 2)
WILC1 0
WILC2 0
WILC3 1 (wk 1 postinfection)
WILC4 0
WILC5 0
Healthy controls
(group 3)
WN1 7 (wk 1, 2, 3, 4, 5, 6, and 7
postinfection)
WN2 1 (wk 8 postinfection)
WN3 4 (wk 4, 5, 6, and 7 postinfection)
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WHcAg in woodchucks vaccinated with pCw. In this group SI
values above 9 were present at several time points in different
animals (P 0.05 versus values for controls). However, despite
substantial IL-2 production, the generation of IFN- in re-
sponse to WHcAg in this group of animals was poor (Fig. 4E).
Very low transcriptional levels of this cytokine were found in
WC2 and WC4, and a single peak of 8 IFN- mRNA copies
per copy of -actin mRNA was observed at week 2 in WC1, the
only woodchuck in this group which showed protection against
infection.
Woodchucks vaccinated with pCw plus pIL12w and exposed
to WHV showed marked increases in IL-2 production in re-
sponse to WHcAg; the frequency of SI values above 9 was
significantly higher than that in controls (P  0.05), and occa-
sional peaks above 20 were observed in four animals (Fig. 4C).
Interestingly, in this group of woodchucks, the increased IL-2
response was associated with high IFN- production. Thus,
woodchucks that received the combined vaccination (and that
were protected against WHV infection) showed values above 5
copies of IFN- mRNA per copy of -actin mRNA with a
frequency significantly higher (P  0.05) than that in the sum
of the animals in the other two experimental groups (which
were unprotected against WHV challenge). High peaks of
IFN- production (more than 25 copies of IFN- mRNA per
copy of -actin) were found in three of the woodchucks that
received the combined immunization (Fig. 4F).
DISCUSSION
It has been shown that specific cellular immunity against
HBcAg plays a crucial role in the control of HBV infection
(13). Several studies have tested the efficacy of vaccines aimed
at enhancing the host’s cellular immune response against
WHcAg, as a means to prevent WHV infection (28, 29, 40).
DNA immunization is an efficient method to stimulate both
cellular and humoral immunity. A previous report (28) has
shown that intramuscular injection of plasmid DNA was able
to induce anti-WHc immunity and protection against infection.
However, a large amount of DNA (2 doses of 100 g followed
by 3 doses of 1 mg) was needed to induce specific anti-WHc
antibodies and protection against virus challenge. In the
present study we used gene gun vaccination because this strat-
egy uses very little amount of plasmid DNA. In experiments
carried out on mice, it was observed that three doses of 2 or 4
g of the plasmid coding for WHcAg (pCw) were equally
effective at inducing anti-WHc antibodies. With woodchucks,
three doses of 8 g of pCw induced antibodies in only one of
the four vaccinated animals, but T-cell proliferation in re-
sponse to WHcAg was found in all vaccinated woodchucks
except WC4 (this animal showed T-cell proliferation and low
titers of anti-WHc antibodies after three additional doses of
the immunogen). However, as shown in Fig. 1B and C, the
proliferative T-cell response elicited by gene gun vaccination
with pCw alone was associated with no or very poor IFN-
production by proliferating T cells, indicating that the type of
Th response generated by this form of vaccination was not Th1.
In our study, gene gun immunization with pCw was not
found to induce protective immunity against WHV infection.
Thus, upon WHV infection, viremias in control woodchucks
and pCw-vaccinated animals were not statistically different. In
fact, one of the woodchucks of the last group (WC3) developed
chronic infection, an event which seldom takes place when
WHV infection occurs after the perinatal period. Cote et al.
(8) reported that the chronicity rate in adult woodchucks was
0% even after inoculation with high doses of the virus.
Interestingly, after WHV infection, woodchucks which had
been vaccinated with pCw alone showed high titers of anti-
WHc antibodies, and the levels of IL-2 synthesis in response to
WHcAg were higher than those in nonimmunized controls
(Fig. 3 and 4A and B). However, in pCw-vaccinated wood-
chucks the synthesis of IFN- mRNA by T cells stimulated
with WHcAg was poor; the transcriptional levels of this cyto-
kine were appreciable only in WC1, the sole animal from this
group which manifested protection against WHV challenge
(Fig. 4E). As WHcAg forms the internal nucleocapsid of
WHV, humoral antibodies to this antigen are not capable of
neutralizing virions, and only T-cell immunity to this antigen
can be efficient in the control of viral replication. IFN- is an
FIG. 3. Anti-WHc (A) and anti-WHs (B) responses in woodchucks after challenge with 1010 WHV genomic particles. Symbols: ‚, nonvacci-
nated animals; }, animals immunized with pCw alone; , animals immunized with pCw plus pIL12w. Mean values at each time point are shown.
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FIG. 4. Cellular immunes response of woodchucks after challenge with 1010 WHV genomic particles at week 0. Data for nonimmunized
woodchucks (WN1 and WN2) (A and D), woodchucks previously vaccinated with pCw (WC1, WC2, WC3, and WC4) (B and E), and woodchucks
previously immunized with pCw plus pIL12w (WILC1, WILC2, WILC3, and WILC4) (C and F) are shown. Determinations of IL-2 production
(A, B, and C) and IFN-mRNA levels (D, E, and F) in PBMC after stimulation with recombinant WHcAg were performed at different time points
during follow-up after infection. IL-2 levels are expressed in terms of the SI. IFN- levels are expressed as the number of IFN- mRNA copies
per copy of -actin mRNA.
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important immunomodulatory cytokine, generated in the Th1
type of immune response, which plays a critical role in orches-
trating protective antiviral T-cell immunity (2, 31). Our data
suggest that the failure of gene gun immunization with pCw
alone to stimulate Th1 reactivity might be responsible for the
lack of protection against WHV infection.
The inability of pCw administered by bombardment of the
skin to achieve protective immunity is in contrast with the
findings of studies (28) showing protection by intramuscu-
lar injection of large amounts of plasmid DNA coding for
WHcAg. This discrepancy could be explained by the inflam-
matory reaction caused by intramuscular injection of the plas-
mid, which could stimulate dendritic cells in the muscle to
synthesize IL-12. Also, degradation of injected DNA by extra-
cellular nucleases will generate abundant CpG motifs, which
would stimulate APCs to synthesize IL-12 (17). IL-12 is a
central cytokine in the induction of IFN- production and the
Th1 type of responses (47). Gene gun procedures use very little
DNA, which is delivered directly to APCs of the skin without
any inflammatory reaction, thus facilitating presentation of the
coded antigen to T cells by nonactivated dendritic cells. This
would prime T cells without IL-12 signaling, leading to a non-
Th1 immune reaction. The inability of gene gun immunization
to stimulate Th1 responses has also been recently reported by
Tanghe et al. (44), who showed that a tuberculosis DNA vac-
cine was protective when given by intramuscular injection but
not when low or high doses of plasmid were administered by
gene gun bombardment of the skin.
The efficacy of IL-12 gene administration as a vaccine adju-
vant to stimulate Th1 responses has been demonstrated previ-
ously by our group (27) as well as by others (41) in murine
models of immunization against HCV antigens and herpesvi-
rus. In the present study, in an attempt to promote a Th1
response leading to protection against WHV infection, we vac-
cinated woodchucks with pCw together with a plasmid coding
for woodchuck IL-12 (pIL12w). This strategy proved to be very
effective at activating Th1 cells and antiviral immunity, result-
ing in production of anti-WHc antibodies, T-cell proliferation,
and production of IFN- in all cases tested (see Fig. 1). These
animals were efficiently protected against infection, showing
undetectable or very low-level and transient viremia after
WHV inoculation. In these woodchucks viral clearance oc-
curred in association with very low titers of anti-WHc and anti-
WHs antibodies, indicating little contribution of humoral im-
munity in the control of viral replication. In contrast to low
antibody titers, woodchucks which had received the combined
vaccination exhibited, after WHV challenge, high levels of IL-2
and IFN- production in response to WHcAg. In comparing
Fig. 4B and C with Fig. 4E and F, it is apparent that while
animals from the two vaccinated groups showed manifest T-
cell proliferation in response to WHcAg, only T cells from the
group immunized with pCw plus pIL12w produced significant
amounts of IFN-. Thus, our findings indicate that the com-
bined genetic vaccination with pCw plus pIL12w results in the
preferential induction of a Th1 immune response, leading to
effective control of WHV replication.
In summary, we show that gene gun vaccination with
WHcAg alone does not protect against WHV challenge. Steer-
ing the immune response toward protective immunity by using
appropriate cytokines as vaccine adjuvants is a feasible and
simple procedure that may prove of value not only in prophy-
lactic but also perhaps in therapeutic vaccination. Our data
highlight the role of the Th1 response in the control of hep-
adnavirus infections and suggest new modalities to induce pro-
tection against HBV infection.
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